Moderna (MRNA) stock slips; Feb. 13 earnings call is the next catalyst for the share price
Moderna shares closed Monday down 1.5% at $47.98 and held steady after hours. The company will report fourth-quarter results and give a corporate update on Feb. 13. Biotech ETFs ended mixed, while big pharma stocks moved unevenly. Moderna’s stock has swung sharply throughout January.